Click here to get full coverage on Recursion Pharmaceuticals RXRX Stock News and Forecasts on December 21 2025 - ts2.tech

Recursion Pharmaceuticals RXRX Stock News and Forecasts on December 21 2025  ts2.tech

Recursion Pharmaceuticals RXRX Stock News and Forecasts on December 21 2025 - ts2.tech

Click here to get full coverage on How Investors May Respond To Recursion Pharmaceuticals (RXRX) Early FAP Trial Success And AI Platform Validation - Yahoo Finance

How Investors May Respond To Recursion Pharmaceuticals (RXRX) Early FAP Trial Success And AI Platform Validation  Yahoo Finance

How Investors May Respond To Recursion Pharmaceuticals (RXRX) Early FAP Trial Success And AI Platform Validation - Yahoo Finance

Click here to get full coverage on Recursion Pharmaceuticals (RXRX) Price Target Increased by 10.53% to 7.14 - Nasdaq

Recursion Pharmaceuticals (RXRX) Price Target Increased by 10.53% to 7.14  Nasdaq

Recursion Pharmaceuticals (RXRX) Price Target Increased by 10.53% to 7.14 - Nasdaq

Click here to get full coverage on Recursion Pharmaceuticals Stock (RXRX) Opinions on Analyst Upgrade and Clinical Data - Quiver Quantitative

Recursion Pharmaceuticals Stock (RXRX) Opinions on Analyst Upgrade and Clinical Data  Quiver Quantitative

Recursion Pharmaceuticals Stock (RXRX) Opinions on Analyst Upgrade and Clinical Data - Quiver Quantitative

Click here to get full coverage on Recursion stock jumps as J.P. Morgan upgrades (RXRX:NASDAQ) - Seeking Alpha

Recursion stock jumps as J.P. Morgan upgrades (RXRX:NASDAQ)  Seeking Alpha

Recursion stock jumps as J.P. Morgan upgrades (RXRX:NASDAQ) - Seeking Alpha

Click here to get full coverage on Recursion Pharmaceuticals (RXRX): Valuation Check After Encouraging TUPELO Trial Data and Analyst Upgrades - Sahm

Recursion Pharmaceuticals (RXRX): Valuation Check After Encouraging TUPELO Trial Data and Analyst Upgrades  Sahm

Recursion Pharmaceuticals (RXRX): Valuation Check After Encouraging TUPELO Trial Data and Analyst Upgrades - Sahm

Click here to get full coverage on RXRX Stock Surges on JPMorgan Upgrade, Trial Data Gains - Forbes

RXRX Stock Surges on JPMorgan Upgrade, Trial Data Gains  Forbes

RXRX Stock Surges on JPMorgan Upgrade, Trial Data Gains - Forbes

Click here to get full coverage on RXRX Stock Insight: Unraveling Latest Developments - timothysykes.com

RXRX Stock Insight: Unraveling Latest Developments  timothysykes.com

RXRX Stock Insight: Unraveling Latest Developments - timothysykes.com

Click here to get full coverage on Is Recursion Pharmaceuticals Stock Attractive? - Trefis

Is Recursion Pharmaceuticals Stock Attractive?  Trefis

Is Recursion Pharmaceuticals Stock Attractive? - Trefis

Click here to get full coverage on RXRX Stock: Analyzing the Dive and Its Impact - StocksToTrade

RXRX Stock: Analyzing the Dive and Its Impact  StocksToTrade

RXRX Stock: Analyzing the Dive and Its Impact - StocksToTrade

Click here to get full coverage on RXRX Stock Today: Insider Selling, CEO Transition and Trial Catalyst Shape Recursion Pharmaceuticals’ Outlook (December 2025) - ts2.tech

RXRX Stock Today: Insider Selling, CEO Transition and Trial Catalyst Shape Recursion Pharmaceuticals’ Outlook (December 2025)  ts2.tech

RXRX Stock Today: Insider Selling, CEO Transition and Trial Catalyst Shape Recursion Pharmaceuticals’ Outlook (December 2025) - ts2.tech

Click here to get full coverage on Recursion (RXRX) Jumps 8% on Bargain-Hunting - Yahoo Finance

Recursion (RXRX) Jumps 8% on Bargain-Hunting  Yahoo Finance

Recursion (RXRX) Jumps 8% on Bargain-Hunting - Yahoo Finance

Click here to get full coverage on Recursion Pharmaceuticals (RXRX) Stock News & Forecast (Dec. 18, 2025): JPMorgan Upgrade, REC-4881 Trial Momentum, and What Analysts See Next - ts2.tech

Recursion Pharmaceuticals (RXRX) Stock News & Forecast (Dec. 18, 2025): JPMorgan Upgrade, REC-4881 Trial Momentum, and What Analysts See Next  ts2.tech

Recursion Pharmaceuticals (RXRX) Stock News & Forecast (Dec. 18, 2025): JPMorgan Upgrade, REC-4881 Trial Momentum, and What Analysts See Next - ts2.tech

Click here to get full coverage on Recursion Pharmaceuticals (RXRX): Valuation Check After Encouraging TUPELO Trial Data and Analyst Upgrades - Yahoo! Finance Canada

Recursion Pharmaceuticals (RXRX): Valuation Check After Encouraging TUPELO Trial Data and Analyst Upgrades  Yahoo! Finance Canada

Recursion Pharmaceuticals (RXRX): Valuation Check After Encouraging TUPELO Trial Data and Analyst Upgrades - Yahoo! Finance Canada

Click here to get full coverage on Recursion Pharmaceuticals Stock (RXRX) Opinions on Exscientia Merger and Clinical Data Readout - Quiver Quantitative

Recursion Pharmaceuticals Stock (RXRX) Opinions on Exscientia Merger and Clinical Data Readout  Quiver Quantitative

Recursion Pharmaceuticals Stock (RXRX) Opinions on Exscientia Merger and Clinical Data Readout - Quiver Quantitative

Click here to get full coverage on Is Recursion Pharmaceuticals, Inc. (RXRX) the Best Fundamentally Strong Penny Stock to Buy? - Yahoo Finance

Is Recursion Pharmaceuticals, Inc. (RXRX) the Best Fundamentally Strong Penny Stock to Buy?  Yahoo Finance

Is Recursion Pharmaceuticals, Inc. (RXRX) the Best Fundamentally Strong Penny Stock to Buy? - Yahoo Finance

Click here to get full coverage on Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next - ts2.tech

Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next  ts2.tech

Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next - ts2.tech

Click here to get full coverage on Will Recursion Pharmaceuticals’ (RXRX) New CEO Accelerate Its AI Ambitions and Strategic Partnerships? - Yahoo Finance

Will Recursion Pharmaceuticals’ (RXRX) New CEO Accelerate Its AI Ambitions and Strategic Partnerships?  Yahoo Finance

Will Recursion Pharmaceuticals’ (RXRX) New CEO Accelerate Its AI Ambitions and Strategic Partnerships? - Yahoo Finance

Click here to get full coverage on Why Recursion Pharmaceuticals, Inc. (RXRX)’s Upside Case Hasn’t Fully Convinced Yet - Yahoo Finance

Why Recursion Pharmaceuticals, Inc. (RXRX)’s Upside Case Hasn’t Fully Convinced Yet  Yahoo Finance

Why Recursion Pharmaceuticals, Inc. (RXRX)’s Upside Case Hasn’t Fully Convinced Yet - Yahoo Finance

Click here to get full coverage on Recursion Pharmaceuticals Stock (RXRX) Opinions on Exscientia Merger and Partnerships - Quiver Quantitative

Recursion Pharmaceuticals Stock (RXRX) Opinions on Exscientia Merger and Partnerships  Quiver Quantitative

Recursion Pharmaceuticals Stock (RXRX) Opinions on Exscientia Merger and Partnerships - Quiver Quantitative

Click here to get full coverage on A Look at Recursion Pharmaceuticals’s Valuation Following New CEO, Narrowed Losses, and Milestone Partnership Payment - Yahoo Finance

A Look at Recursion Pharmaceuticals’s Valuation Following New CEO, Narrowed Losses, and Milestone Partnership Payment  Yahoo Finance

A Look at Recursion Pharmaceuticals’s Valuation Following New CEO, Narrowed Losses, and Milestone Partnership Payment - Yahoo Finance

Click here to get full coverage on Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory - Yahoo Finance

Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory  Yahoo Finance

Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory - Yahoo Finance

Click here to get full coverage on JP Morgan Upgrades Recursion Pharmaceuticals (RXRX) - Nasdaq

JP Morgan Upgrades Recursion Pharmaceuticals (RXRX)  Nasdaq

JP Morgan Upgrades Recursion Pharmaceuticals (RXRX) - Nasdaq

Click here to get full coverage on Recursion Pharmaceuticals (RXRX): Annual Losses Widen 35.2% Despite 30.1% Forecast Revenue Growth - Yahoo Finance

Recursion Pharmaceuticals (RXRX): Annual Losses Widen 35.2% Despite 30.1% Forecast Revenue Growth  Yahoo Finance

Recursion Pharmaceuticals (RXRX): Annual Losses Widen 35.2% Despite 30.1% Forecast Revenue Growth - Yahoo Finance

Click here to get full coverage on Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025 (RXRX) - Seeking Alpha

Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025 (RXRX)  Seeking Alpha

Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025 (RXRX) - Seeking Alpha

Click here to get full coverage on Recursion Pharmaceuticals (RXRX) Climbs 16% Ahead of AI Conference - Yahoo Finance

Recursion Pharmaceuticals (RXRX) Climbs 16% Ahead of AI Conference  Yahoo Finance

Recursion Pharmaceuticals (RXRX) Climbs 16% Ahead of AI Conference - Yahoo Finance

Click here to get full coverage on Recursion Pharmaceuticals (RXRX) Extends Gains, Jumps 15.28% on Major AI Event - Yahoo Finance

Recursion Pharmaceuticals (RXRX) Extends Gains, Jumps 15.28% on Major AI Event  Yahoo Finance

Recursion Pharmaceuticals (RXRX) Extends Gains, Jumps 15.28% on Major AI Event - Yahoo Finance

Click here to get full coverage on Needham Reiterates a Buy on Recursion Pharmaceuticals (RXRX) - Yahoo Finance

Needham Reiterates a Buy on Recursion Pharmaceuticals (RXRX)  Yahoo Finance

Needham Reiterates a Buy on Recursion Pharmaceuticals (RXRX) - Yahoo Finance

Click here to get full coverage on Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance

Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know  Yahoo Finance

Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance

Click here to get full coverage on Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance

Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key Insights  Yahoo Finance

Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance

Click here to get full coverage on RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y - Yahoo Finance

RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y  Yahoo Finance

RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y - Yahoo Finance

Click here to get full coverage on Recursion Pharmaceuticals stock upgraded by JPMorgan on MEK inhibitor potential - Investing.com

Recursion Pharmaceuticals stock upgraded by JPMorgan on MEK inhibitor potential  Investing.com

Recursion Pharmaceuticals stock upgraded by JPMorgan on MEK inhibitor potential - Investing.com

Click here to get full coverage on Recursion Pharmaceuticals (RXRX): Assessing Valuation Following AI Merger News, Trial Progress, and Regulatory Updates - Yahoo Finance

Recursion Pharmaceuticals (RXRX): Assessing Valuation Following AI Merger News, Trial Progress, and Regulatory Updates  Yahoo Finance

Recursion Pharmaceuticals (RXRX): Assessing Valuation Following AI Merger News, Trial Progress, and Regulatory Updates - Yahoo Finance

Click here to get full coverage on Recursion Pharmaceuticals Stock (RXRX) Opinions on Q3 Earnings Miss - Quiver Quantitative

Recursion Pharmaceuticals Stock (RXRX) Opinions on Q3 Earnings Miss  Quiver Quantitative

Recursion Pharmaceuticals Stock (RXRX) Opinions on Q3 Earnings Miss - Quiver Quantitative

Click here to get full coverage on Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 220,000 Shares of Stock - MarketBeat

Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 220,000 Shares of Stock  MarketBeat

Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 220,000 Shares of Stock - MarketBeat

Click here to get full coverage on Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know - Yahoo Finance

Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know  Yahoo Finance

Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know - Yahoo Finance

Click here to get full coverage on RXRX, FTNT, MRK, RIVN, PYPL Trending With Analysts - TipRanks

RXRX, FTNT, MRK, RIVN, PYPL Trending With Analysts  TipRanks

RXRX, FTNT, MRK, RIVN, PYPL Trending With Analysts - TipRanks

Click here to get full coverage on What Recursion Pharmaceuticals (RXRX)'s FAP Trial Win And AI Platform Validation Means For Shareholders - Sahm

What Recursion Pharmaceuticals (RXRX)'s FAP Trial Win And AI Platform Validation Means For Shareholders  Sahm

What Recursion Pharmaceuticals (RXRX)'s FAP Trial Win And AI Platform Validation Means For Shareholders - Sahm

Click here to get full coverage on Recursion Pharmaceuticals Is Down 88% From Record Highs. Is RXRX Stock Finally a Good Buy? - TIKR.com

Recursion Pharmaceuticals Is Down 88% From Record Highs. Is RXRX Stock Finally a Good Buy?  TIKR.com

Recursion Pharmaceuticals Is Down 88% From Record Highs. Is RXRX Stock Finally a Good Buy? - TIKR.com

Click here to get full coverage on Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings - Yahoo Finance

Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings  Yahoo Finance

Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings - Yahoo Finance

Click here to get full coverage on Recursion Pharmaceuticals (RXRX): Assessing Valuation with AI Strategy in Focus Ahead of Key CEO Presentation - Yahoo Finance

Recursion Pharmaceuticals (RXRX): Assessing Valuation with AI Strategy in Focus Ahead of Key CEO Presentation  Yahoo Finance

Recursion Pharmaceuticals (RXRX): Assessing Valuation with AI Strategy in Focus Ahead of Key CEO Presentation - Yahoo Finance

Click here to get full coverage on Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? - The Motley Fool

Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock?  The Motley Fool

Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? - The Motley Fool

Click here to get full coverage on Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates  Yahoo Finance

Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on Recursion Pharmaceuticals: Artificial Intelligence, Real Disappointment (RXRX) - Seeking Alpha

Recursion Pharmaceuticals: Artificial Intelligence, Real Disappointment (RXRX)  Seeking Alpha

Recursion Pharmaceuticals: Artificial Intelligence, Real Disappointment (RXRX) - Seeking Alpha

Click here to get full coverage on $RXRX stock fell 9% this week. Here's what we see in our data. - Quiver Quantitative

$RXRX stock fell 9% this week. Here's what we see in our data.  Quiver Quantitative

$RXRX stock fell 9% this week. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 Advances - Yahoo Finance

Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 Advances  Yahoo Finance

Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 Advances - Yahoo Finance

Click here to get full coverage on Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue? - Nasdaq

Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue?  Nasdaq

Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue? - Nasdaq

Click here to get full coverage on Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance

Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors  Yahoo Finance

Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance

Click here to get full coverage on Cathie Wood’s ARK sells Tesla stock, buys Coinbase and Recursion Pharmaceuticals - Investing.com

Cathie Wood’s ARK sells Tesla stock, buys Coinbase and Recursion Pharmaceuticals  Investing.com

Cathie Wood’s ARK sells Tesla stock, buys Coinbase and Recursion Pharmaceuticals - Investing.com

Click here to get full coverage on Recursion Pharmaceuticals (RXRX) Sees Sales And Revenue Growth In Q2 2025 - Yahoo Finance

Recursion Pharmaceuticals (RXRX) Sees Sales And Revenue Growth In Q2 2025  Yahoo Finance

Recursion Pharmaceuticals (RXRX) Sees Sales And Revenue Growth In Q2 2025 - Yahoo Finance

Click here to get full coverage on New Analyst Forecast: $RXRX Given $11 Price Target - Quiver Quantitative

New Analyst Forecast: $RXRX Given $11 Price Target  Quiver Quantitative

New Analyst Forecast: $RXRX Given $11 Price Target - Quiver Quantitative

Click here to get full coverage on $RXRX stock fell 17% this week. Here's what we see in our data. - Quiver Quantitative

$RXRX stock fell 17% this week. Here's what we see in our data.  Quiver Quantitative

$RXRX stock fell 17% this week. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Recursion Pharmaceuticals (RXRX) Drops on 3rd Day as Company Execs Dispose of Shares - Yahoo Finance

Recursion Pharmaceuticals (RXRX) Drops on 3rd Day as Company Execs Dispose of Shares  Yahoo Finance

Recursion Pharmaceuticals (RXRX) Drops on 3rd Day as Company Execs Dispose of Shares - Yahoo Finance

Click here to get full coverage on Recursion Pharmaceuticals (RXRX) Stock: CEO Sells $5.8 Million in Shares Following Exscientia Merger - CoinCentral

Recursion Pharmaceuticals (RXRX) Stock: CEO Sells $5.8 Million in Shares Following Exscientia Merger  CoinCentral

Recursion Pharmaceuticals (RXRX) Stock: CEO Sells $5.8 Million in Shares Following Exscientia Merger - CoinCentral

Click here to get full coverage on What Recursion Pharmaceuticals (RXRX)'s FAP Trial Win And AI Platform Validation Means For Shareholders - simplywall.st

What Recursion Pharmaceuticals (RXRX)'s FAP Trial Win And AI Platform Validation Means For Shareholders  simplywall.st

What Recursion Pharmaceuticals (RXRX)'s FAP Trial Win And AI Platform Validation Means For Shareholders - simplywall.st

Click here to get full coverage on Is Recursion Pharmaceuticals, Inc. (RXRX) the best fundamentally strong penny stock to buy? - MSN

Is Recursion Pharmaceuticals, Inc. (RXRX) the best fundamentally strong penny stock to buy?  MSN

Is Recursion Pharmaceuticals, Inc. (RXRX) the best fundamentally strong penny stock to buy? - MSN

Click here to get full coverage on Recursion Pharmaceuticals (RXRX) Is Up 6.0% After New AI Partnerships and Exscientia Acquisition Has the Bull Case Changed? - Yahoo Finance

Recursion Pharmaceuticals (RXRX) Is Up 6.0% After New AI Partnerships and Exscientia Acquisition Has the Bull Case Changed?  Yahoo Finance

Recursion Pharmaceuticals (RXRX) Is Up 6.0% After New AI Partnerships and Exscientia Acquisition Has the Bull Case Changed? - Yahoo Finance

Click here to get full coverage on Recursion Pharmaceuticals Stock (RXRX) Opinions on Exscientia Merger and TUPELO Trial Data - Quiver Quantitative

Recursion Pharmaceuticals Stock (RXRX) Opinions on Exscientia Merger and TUPELO Trial Data  Quiver Quantitative

Recursion Pharmaceuticals Stock (RXRX) Opinions on Exscientia Merger and TUPELO Trial Data - Quiver Quantitative

Click here to get full coverage on Recursion Pharmaceuticals (RXRX) Drops on Profit-Taking - Yahoo Finance

Recursion Pharmaceuticals (RXRX) Drops on Profit-Taking  Yahoo Finance

Recursion Pharmaceuticals (RXRX) Drops on Profit-Taking - Yahoo Finance

Click here to get full coverage on Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid - Yahoo Finance

Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid  Yahoo Finance

Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid - Yahoo Finance

Click here to get full coverage on Recursion Pharmaceuticals: Is It the Right Time to Buy? - StocksToTrade

Recursion Pharmaceuticals: Is It the Right Time to Buy?  StocksToTrade

Recursion Pharmaceuticals: Is It the Right Time to Buy? - StocksToTrade

Click here to get full coverage on Analysts Are Bullish on These Healthcare Stocks: Novan (NOVN), Recursion Pharmaceuticals (RXRX) - The Globe and Mail

Analysts Are Bullish on These Healthcare Stocks: Novan (NOVN), Recursion Pharmaceuticals (RXRX)  The Globe and Mail

Analysts Are Bullish on These Healthcare Stocks: Novan (NOVN), Recursion Pharmaceuticals (RXRX) - The Globe and Mail

Click here to get full coverage on Recursion Pharmaceuticals, Inc. (RXRX) Expands Rare Disease Pipeline with REV102 Acquisition - Yahoo Finance

Recursion Pharmaceuticals, Inc. (RXRX) Expands Rare Disease Pipeline with REV102 Acquisition  Yahoo Finance

Recursion Pharmaceuticals, Inc. (RXRX) Expands Rare Disease Pipeline with REV102 Acquisition - Yahoo Finance

Click here to get full coverage on RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now? - Yahoo Finance

RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?  Yahoo Finance

RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now? - Yahoo Finance

Click here to get full coverage on Recursion Pharmaceuticals (NASDAQ:RXRX) Nasdaq Index Fund Spotlight - Kalkine Media

Recursion Pharmaceuticals (NASDAQ:RXRX) Nasdaq Index Fund Spotlight  Kalkine Media

Recursion Pharmaceuticals (NASDAQ:RXRX) Nasdaq Index Fund Spotlight - Kalkine Media

Click here to get full coverage on Recursion Pharmaceuticals (RXRX): Revisiting Valuation After a Tentative Share Price Rebound - Sahm

Recursion Pharmaceuticals (RXRX): Revisiting Valuation After a Tentative Share Price Rebound  Sahm

Recursion Pharmaceuticals (RXRX): Revisiting Valuation After a Tentative Share Price Rebound - Sahm

Click here to get full coverage on $RXRX stock is up 5% today. Here's what we see in our data. - Quiver Quantitative

$RXRX stock is up 5% today. Here's what we see in our data.  Quiver Quantitative

RXRX

Price Chart

Key Statistics

Technicals

About RXRX

Latest News

Recursion Pharmaceuticals RXRX Stock News and Forecasts on December 21 2025 - ts2.tech

How Investors May Respond To Recursion Pharmaceuticals (RXRX) Early FAP Trial Success And AI Platform Validation - Yahoo Finance

Recursion Pharmaceuticals (RXRX) Price Target Increased by 10.53% to 7.14 - Nasdaq

Advanced Charts

Top Gainers

Top Losers